These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 23248244)

  • 1. Cabozantinib in prostate cancer: the beginning of a precision paradigm?
    Goodin S; DiPaola RS
    J Clin Oncol; 2013 Feb; 31(4):401-3. PubMed ID: 23248244
    [No Abstract]   [Full Text] [Related]  

  • 2. Commentary on "Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial." Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin CC, Srinivas S, Sella A, SchoffskiSchöffski P, Scheffold C, Weitzman AL, Hussain M, University of Michigan, Ann Arbor, MI. J Clin Oncol 2013;31(4):412-9. doi: 10.1200/JCO.2012.45.0494. Epub 2012 Nov 19.
    Trump DL
    Urol Oncol; 2013 Nov; 31(8):1848. PubMed ID: 24210087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.
    Smith DC; Smith MR; Sweeney C; Elfiky AA; Logothetis C; Corn PG; Vogelzang NJ; Small EJ; Harzstark AL; Gordon MS; Vaishampayan UN; Haas NB; Spira AI; Lara PN; Lin CC; Srinivas S; Sella A; Schöffski P; Scheffold C; Weitzman AL; Hussain M
    J Clin Oncol; 2013 Feb; 31(4):412-9. PubMed ID: 23169517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current role of cabozantinib in metastatic castration-resistant prostate cancer.
    Fay AP; Albiges L; Bellmunt J
    Expert Rev Anticancer Ther; 2015 Feb; 15(2):151-6. PubMed ID: 25586337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer.
    Di Nunno V; Cimadamore A; Santoni M; Scarpelli M; Fiorentino M; Ciccarese C; Iacovelli R; Cheng L; Lopez-Beltran A; Massari F; Montironi R
    Future Oncol; 2018 Oct; 14(25):2559-2564. PubMed ID: 30141348
    [No Abstract]   [Full Text] [Related]  

  • 6. Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma.
    Pinto A
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):219-22. PubMed ID: 24202668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer: cabozantinib reduces pain and narcotic use in men with CRPC.
    Clyne M
    Nat Rev Urol; 2014 Apr; 11(4):188. PubMed ID: 24619377
    [No Abstract]   [Full Text] [Related]  

  • 8. Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).
    Bowles DW; Kessler ER; Jimeno A
    Drugs Today (Barc); 2011 Nov; 47(11):857-68. PubMed ID: 22146228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cabozantinib as an emerging treatment for sarcoma.
    Schöffski P; Blay JY; Ray-Coquard I
    Curr Opin Oncol; 2020 Jul; 32(4):321-331. PubMed ID: 32541320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.
    Varkaris A; Corn PG; Parikh NU; Efstathiou E; Song JH; Lee YC; Aparicio A; Hoang AG; Gaur S; Thorpe L; Maity SN; Bar Eli M; Czerniak BA; Shao Y; Alauddin M; Lin SH; Logothetis CJ; Gallick GE
    Clin Cancer Res; 2016 Jan; 22(1):107-21. PubMed ID: 26272062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cabozantinib for the treatment of renal cell carcinoma.
    Escudier B; Lougheed JC; Albiges L
    Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cabozantinib Unlocks Efficient
    Chaudagar KK; Landon-Brace N; Solanki A; Hieromnimon HM; Hegermiller E; Li W; Shao Y; Joseph J; Wilkins DJ; Bynoe KM; Li XL; Clohessy JG; Ullas S; Karp JM; Patnaik A
    Mol Cancer Ther; 2021 Feb; 20(2):438-449. PubMed ID: 33277441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma.
    Lendvai N; Yee AJ; Tsakos I; Alexander A; Devlin SM; Hassoun H; Korde N; Lesokhin AM; Landau H; Mailankody S; Koehne G; Chung DJ; Landgren O; Raje NS; Giralt S
    Blood; 2016 May; 127(19):2355-6. PubMed ID: 27020089
    [No Abstract]   [Full Text] [Related]  

  • 14. Early and persisting response to vismodegib in a patient with bone metastasizing medulloblastoma.
    Asklund T; Henriksson R; Axelsson J; Bergström Å; Kasper M; Ögren M; Toftgård R; Riklund KÅ
    Acta Oncol; 2013 May; 52(4):862-6. PubMed ID: 23013267
    [No Abstract]   [Full Text] [Related]  

  • 15. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor.
    Grüllich C
    Recent Results Cancer Res; 2014; 201():207-14. PubMed ID: 24756794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabozantinib in ovarian clear cell cancers: UnMET expectations.
    Secord AA; Previs RA; Nixon AB
    Gynecol Oncol; 2018 Jul; 150(1):1-2. PubMed ID: 29935857
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.
    Smith M; De Bono J; Sternberg C; Le Moulec S; Oudard S; De Giorgi U; Krainer M; Bergman A; Hoelzer W; De Wit R; Bögemann M; Saad F; Cruciani G; Thiery-Vuillemin A; Feyerabend S; Miller K; Houédé N; Hussain S; Lam E; Polikoff J; Stenzl A; Mainwaring P; Ramies D; Hessel C; Weitzman A; Fizazi K
    J Clin Oncol; 2016 Sep; 34(25):3005-13. PubMed ID: 27400947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabozantinib in Advanced Renal Cell Carcinoma: Is it a METEOR?
    Ciccarese C; Massari F; Tortora G
    Eur Urol; 2016 May; 69(5):969-70. PubMed ID: 26724839
    [No Abstract]   [Full Text] [Related]  

  • 19. Cabozantinib and nivolumab for renal cell carcinoma.
    Worley L
    Lancet Oncol; 2015 Nov; 16(15):e531. PubMed ID: 26481805
    [No Abstract]   [Full Text] [Related]  

  • 20. Kidney cancer: CheckMate for advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor survival.
    Thoma C
    Nat Rev Clin Oncol; 2015 Nov; 12(11):621. PubMed ID: 26462125
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.